Zhang GJ and Adachi I. Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. Int J Oncol, 1999; 14: 71-77. Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, Funahashi H, and Takagi H. Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases. Jpn J Clin Oncol, 1997; 27: 135-139.

Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, Funahashi H, and Takagi H. Increased concentration of soluble E-selectin in the sera of breast cancer patients. Anticancer Res, 1997; 17: 1367-1372. McEver RP, Moore KL, and Cummings RD. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem, 1995; 270: 11025-11028.

127. Ma YQ. and Geng JG. Obligatory requirement of sulfation for P-selectin binding to human salivary gland carcinoma Acc-M cells and breast carcinoma ZR-75-30 cells. J Immunol, 2002; 168: 1690-1696.

128. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, and Ley K. CD24 mediates rolling of breast carcinoma cells on P-selectin. Faseb J, 1998; 12: 1241-1251.

129. Aruffo A, Dietsch MT, Wan H, Hellstrom KE, and Hellstrom I. Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines. Proc Natl Acad Sci U S A, 1992; 89: 2292-2296.

130. Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, and Lip GY. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis, 2001; 12: 43-50.

131. Laubli H, Stevenson JL, Varki A, Varki NM, and Borsig L. L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest. Cancer Res, 2006; 66: 1536-1542.

132. Borsig L, Wong R, Hynes RO, Varki NM, and Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A, 2002; 99: 2193-2198.

133. Yamada M, Yanaba K, Hasegawa M, Matsushita Y, Horikawa M, Komura K, Matsushita T, Kawasuji A, Fujita T, Takehara K, Steeber DA, Tedder TF, and Sato S. Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1. Clin Exp Immunol, 2006; 143: 216-227.

134. Yamada M, Yanaba K, Takehara K, and Sato S. Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma. Arch Dermatol Res, 2005; 297: 256-260.

135. Chen S, Kawashima H, Lowe JB, Lanier LL, and Fukuda M. Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J Exp Med, 2005; 202: 1679-1689.

136. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 1992; 69: 11-25.

137. Albelda SM and Buck CA. Integrins and other cell adhesion molecules. Faseb J, 1990; 4: 2868-2880.

138. Nair KS, Naidoo R, and Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol, 2005; 58: 343-351.

139. Hood JD. and Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer, 2002; 2: 91-100.

140. Rust WL, Carper SW, and Plopper GE. The Promise of Integrins as Effective Targets for Anticancer Agents. J Biomed Biotechnol, 2002; 2: 124-130.

141. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med, 1999; 222: 124-138.

142. Koukoulis GK, Howeedy AA, Korhonen M, Virtanen I, and Gould VE. Distribution of tenascin, cellular fibronectins and integrins in the normal, hyperplastic and neoplastic breast. J Submicrosc Cytol Pathol, 1993; 25: 285-295.

143. Howlett AR, Bailey N, Damsky C, Petersen OW, and Bissell M J. Cellular growth and survival are mediated by beta 1 integrins in normal human breast epithelium but not in breast carcinoma. J Cell Sci, 1995; 108 (Pt 5): 1945-1957.

144. Damjanovich L, Fulop B, Adany R, and Nemes Z. Integrin expression on normal and neoplastic human breast epithelium. Acta Chir Hung, 1997; 36: 69-71.

Zutter MM, Krigman HR, and Santoro SA. Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am J Pathol, 1993; 142: 1439-1448.

Zutter MM, Sun H, and Santoro SA. Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors. J Mammary Gland Biol Neoplasia, 1998; 3: 191-200.

Hata H, Matsuzaki H, Takeya M, Yoshida M, Sonoki T, Nagasaki A, Kuribayashi N, Kawano F, and Takatsuki K. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood, 1995; 86: 1939-1945.

Green, L. J, Mould, A. P, and Humphries, M. J. The integrin beta subunit. Int J Biochem Cell Biol, 1998; 30: 179-184.

Wong NC, Mueller BM, Barbas CF, Ruminski P, Quaranta V, Lin EC, and Smith JW. Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis, 1998; 16: 50-61. Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, and Strongin AY. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer, 2000; 86: 15-23. Tuck AB, Elliott BE, Hota C, Tremblay E, and Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem, 2000; 78: 465-475.

Bartsch JE, Staren ED, and Appert HE. Adhesion and migration of extracellular matrix-stimulated breast cancer. J Surg Res, 2003; 110: 287-294. Rolli M, Fransvea E, Pilch J, Saven A, and Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA, 2003; 100: 9482-9487.

Meyer T, Marshall JF, and Hart IR. Expression of alphav integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer, 1998; 77: 530-536. Wewer UM, Shaw LM, Albrechtsen R, and Mercurio AM. The integrin alpha 6 beta 1 promotes the survival of metastatic human breast carcinoma cells in mice. Am J Pathol, 1997; 151: 1191-1198.

Chung J. and Mercurio AM. Contributions of the alpha6 integrins to breast carcinoma survival and progression. Mol Cells, 2004; 17: 203-209. Chung J, Yoon S, Datta K, Bachelder RE, and Mercurio AM. Hypoxia-induced vascular endothelial growth factor transcription and protection from apoptosis are dependent on alpha6beta1 integrin in breast carcinoma cells. Cancer Res, 2004; 64: 4711-4716.

Shaw LM. Integrin function in breast carcinoma progression. J Mammary Gland Biol Neoplasia, 1999; 4: 367-376.

Shimizu H, Seiki T, Asada M, Yoshimatsu K, and Koyama N. Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells. Oncogene, 2003; 22: 831-839.

Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK, and Anderson R. L. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res, 2006; 8: R20.

Takayama S, Ishii S, Ikeda T, Masamura S, Doi M, and Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res, 2005; 25: 79-83. Karadag A, Ogbureke KU, Fedarko NS, and Fisher LW. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst, 2004; 96: 956-965.

163. Harms JF, Welch DR, Samant RS, Shevde LA, Miele ME, Babu GR, Goldberg SF, Gilman VR, Sosnowski DM, Campo DA, Gay CV, Budgeon LR, Mercer R, Jewell J, Mastro AM, Donahue HJ, Erin N, Debies MT, Meehan WJ, Jones AL, Mbalaviele G, Nickols A, Christensen ND, Melly R, Beck LN, Kent J, Rader RK, Kotyk JJ, Pagel MD, Westlin WF, and Griggs DW. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis, 2004; 21: 119-128.

164. Alford D, Pitha-Rowe P, and Taylor-Papadimitriou J. Adhesion molecules in breast cancer: role of alpha 2 beta 1 integrin. Biochem Soc Symp, 1998; 63: 245-259.

165. Gui GP, Wells CA, Browne PD, Yeomans P, Jordan S Puddefoot JR, Vinson GP, and Carpenter R. Integrin expression in primary breast cancer and its relation to axillary nodal status. Surgery, 1995; 117: 102-108.

166. Gui GP, Wells CA, Yeomans P, Jordan SE, Vinson GP, and Carpenter R. Integrin expression in breast cancer cytology: a novel predictor of axillary metastasis. Eur J Surg Oncol, 1996; 22: 254-258.

167. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, and Bissell MJ. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol, 1997; 137: 231-245.

168. Weaver VM. and Bissell MJ. Functional culture models to study mechanisms governing apoptosis in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia, 1999; 4: 193-201.

169. Lipscomb EA, Simpson KJ, Lyle SR, Ring JE, Dugan AS, and Mercurio AM. The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res, 2005; 65: 10970-10976.

170. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G, and Giancotti FG. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell, 2006; 126: 489-502.

171. Spangenberg C, Lausch EU, Trost TM, Prawitt D, May A, Keppler R, Fees SA, Reutzel D, Bell C, Schmitt S, Schiffer IB, Weber A, Brenner W, Hermes M, Sahin U, Tureci O, Koelbl H, Hengstler JG, and Zabel BU. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res, 2006; 66: 3715-3725.

172. Yoon SO, Shin S, and Lipscomb EA. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling. Cancer Res, 2006; 66: 2732-2739.

173. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, and Mercurio AM. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol, 2002; 158: 165-174.

174. Yoon SO, Shin S, and Mercurio AM. Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells. Cancer Res, 2006; 66: 6288-6295.

175. Chen M and O'Connor KL. Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene, 2005; 24: 5125-5130.

176. Gilcrease MZ, Zhou X, and Welch K. Adhesion-independent alpha6beta4 integrin clustering is mediated by phosphatidylinositol 3-kinase. Cancer Res, 2004; 64: 7395-7398.

177. Litvinov SV, Bakker HA, Gourevitch MM, Velders MP, and Warnaar SO. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun, 1994; 2: 417-428.

178. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, Fleuren GJ, and Warnaar SO. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol, 1997; 139: 1337-1348.

179. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, and Gillanders WE. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res, 2004; 64: 5818-5824.

180. Gastl G, Spizzo G, Obrist P, Dunser M, and Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet, 2000; 356: 1981-1982.

181. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Kochli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, and Gastl G. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat, 2004; 86: 207-213.

182. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia, 2001; 6: 339-353.

183. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, and Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers, 2000; 15: 343-356.

184. Rahn JJ, Shen Q, Mah BK, and Hugh JC. MUC1 initiates a calcium signal after ligation by intercellular adhesion molecule-1. J Biol Chem, 2004; 279: 2938629390.

185. Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, and Hugh JC. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res, 1996; 56: 4244-4249.

186. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, and Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol, 1995; 129: 255-265.

187. Berry N, Jones DB, Smallwood J, Taylor I, Kirkham N, and Taylor-Papadimitriou J. The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Br J Cancer, 1985; 51: 179-186.

188. Ligtenberg MJ, Buijs F, Vos HL, and Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res, 1992; 52: 2318-2324.

189. Hilkens J, Vos HL, Wesseling J, Boer M, Storm J, van der Valk S, Calafat J, and Patriarca C. Is episialin/MUC1 involved in breast cancer progression? Cancer Lett, 1995; 90: 27-33.

190. Kondo K, Kohno N, Yokoyama A, and Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res, 1998; 58: 2014-2019.

191. Walsh MD, Luckie SM, Cummings MC, Antalis TM, and McGuckin MA. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res Treat, 1999; 58: 255-266.

192. Lu L, Deng HY, and Fan WK. [Correlation of MUC1 expression to adhesion of breast cancer cell line MDA-MB-231.]. Ai Zheng, 2004; 23: 1294-1296.

193. Duffy MJ, Shering S, Sherry F, McDermott E, and O'Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers, 2000; 15: 330-333.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment